Literature DB >> 17718856

Utility of molecular analyses in the exploration of extreme intrafamilial variability in the Marfan syndrome.

J De Backer1, B Loeys, B Leroy, P Coucke, H Dietz, A De Paepe.   

Abstract

The diagnosis of Marfan syndrome may be hampered by the existence of very mild and atypical cases as well as by marked intrafamilial variability. In these instances, molecular analysis of the fibrillin-1 gene (FBN1) can be helpful to identify individuals at risk. The underlying molecular mechanism for the clinical variability is presently unknown. We performed clinical and molecular studies in 36 subjects from three unrelated families. Expression studies of both FBN1 alleles were performed and related to the clinical severity. In family 1, an overlapping phenotype between Marfan syndrome (MFS) and Weill-Marchesani syndrome is presented. The diagnosis necessitated molecular studies and clinical examination in first-degree relatives. In family 2, the young proband presented with a phenotype overlapping between MFS and the kyphoscoliotic type of Ehlers-Danlos syndrome. Follow-up over time and identification of a FBN1 mutation allowed confirmation of the diagnosis. Mutation analysis enabled us to identify family members with mild expression. Family 3 illustrates the extensive intrafamilial variability in the clinical severity of MFS. Identification of a FBN1 mutation was helpful to identify subjects with mild expression and for the timely diagnosis in a neonate. In families 2 and 3, the relative expression of both FBN1 alleles was not related to clinical severity. We demonstrated that confirmation of the diagnosis of MFS may require detailed and repeated clinical evaluation and thorough family history taking. FBN1 mutation analysis is supportive for the diagnosis in mild and atypical presentations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17718856     DOI: 10.1111/j.1399-0004.2007.00845.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  20 in total

1.  Clinical utility gene card for: Marfan syndrome type 1 and related phenotypes [FBN1].

Authors:  Mine Arslan-Kirchner; Eloisa Arbustini; Catherine Boileau; Anne Child; Gwenaelle Collod-Beroud; Anne De Paepe; Jörg Epplen; Guillaume Jondeau; Bart Loeys; Laurence Faivre
Journal:  Eur J Hum Genet       Date:  2010-04-07       Impact factor: 4.246

2.  Genetic diagnostics of inherited aortic diseases : Medical strategy analysis.

Authors:  Y von Kodolitsch; K Kutsche
Journal:  Herz       Date:  2017-08       Impact factor: 1.443

Review 3.  Epigenetic influences on genetically triggered thoracic aortic aneurysm.

Authors:  Stefanie S Portelli; Elizabeth N Robertson; Cassandra Malecki; Kiersten A Liddy; Brett D Hambly; Richmond W Jeremy
Journal:  Biophys Rev       Date:  2018-09-28

Review 4.  FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders.

Authors:  Lynn Y Sakai; Douglas R Keene; Marjolijn Renard; Julie De Backer
Journal:  Gene       Date:  2016-07-18       Impact factor: 3.688

5.  Recurrent and founder mutations in the Netherlands: Extensive clinical variability in Marfan syndrome patients with a single novel recurrent fibrillin-1 missense mutation.

Authors:  J J J Aalberts; A G Schuurman; G Pals; B J C Hamel; G Bosman; Y Hilhorst-Hofstee; D Q C M Barge-Schaapveld; B J M Mulder; M P van den Berg; J P van Tintelen
Journal:  Neth Heart J       Date:  2010-02       Impact factor: 2.380

6.  The importance of genetic testing in the clinical management of patients with Marfan syndrome and related disorders.

Authors:  Mine Arslan-Kirchner; Yskert von Kodolitsch; Jörg Schmidtke
Journal:  Dtsch Arztebl Int       Date:  2008-07-04       Impact factor: 5.594

7.  Microenvironmental regulation by fibrillin-1.

Authors:  Gerhard Sengle; Ko Tsutsui; Douglas R Keene; Sara F Tufa; Eric J Carlson; Noe L Charbonneau; Robert N Ono; Takako Sasaki; Mary K Wirtz; John R Samples; Liselotte I Fessler; John H Fessler; Kiyotoshi Sekiguchi; Susan J Hayflick; Lynn Y Sakai
Journal:  PLoS Genet       Date:  2012-01-05       Impact factor: 5.917

8.  Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial.

Authors:  Teodora Radonic; Piet de Witte; Marieke J H Baars; Aeilko H Zwinderman; Barbara J M Mulder; Maarten Groenink
Journal:  Trials       Date:  2010-01-12       Impact factor: 2.279

9.  Musculo-skeletal abnormalities in patients with Marfan syndrome.

Authors:  Ali Al Kaissi; Elisabeth Zwettler; Rudolf Ganger; Simone Schreiner; Klaus Klaushofer; Franz Grill
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2013-01-29

Review 10.  The Molecular Genetics of Marfan Syndrome.

Authors:  Qiu Du; Dingding Zhang; Yue Zhuang; Qiongrong Xia; Taishen Wen; Haiping Jia
Journal:  Int J Med Sci       Date:  2021-05-27       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.